JP2024514935A - ＩｇＥ抗体を含む組成物 - Google Patents

ＩｇＥ抗体を含む組成物 Download PDF

Info

Publication number
JP2024514935A
JP2024514935A JP2023564409A JP2023564409A JP2024514935A JP 2024514935 A JP2024514935 A JP 2024514935A JP 2023564409 A JP2023564409 A JP 2023564409A JP 2023564409 A JP2023564409 A JP 2023564409A JP 2024514935 A JP2024514935 A JP 2024514935A
Authority
JP
Japan
Prior art keywords
frα
antibody
ige
subject
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514935A5 (https=
JPWO2022223784A5 (https=
Inventor
ジェームズ スパイサー
ソフィア カラジアニス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2021/060749 external-priority patent/WO2021214329A1/en
Priority claimed from GBGB2109550.0A external-priority patent/GB202109550D0/en
Application filed by Kings College London filed Critical Kings College London
Publication of JP2024514935A publication Critical patent/JP2024514935A/ja
Publication of JP2024514935A5 publication Critical patent/JP2024514935A5/ja
Publication of JPWO2022223784A5 publication Critical patent/JPWO2022223784A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2023564409A 2021-04-23 2022-04-22 ＩｇＥ抗体を含む組成物 Pending JP2024514935A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2021/060749 WO2021214329A1 (en) 2020-04-24 2021-04-23 Composition comprising an ige antibody
EPPCT/EP2021/060749 2021-04-23
GBGB2109550.0A GB202109550D0 (en) 2021-07-01 2021-07-01 Composition
GB2109550.0 2021-07-01
PCT/EP2022/060693 WO2022223784A1 (en) 2021-04-23 2022-04-22 Composition comprising an ige antibody

Publications (3)

Publication Number Publication Date
JP2024514935A true JP2024514935A (ja) 2024-04-03
JP2024514935A5 JP2024514935A5 (https=) 2025-04-18
JPWO2022223784A5 JPWO2022223784A5 (https=) 2025-04-18

Family

ID=81750377

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564409A Pending JP2024514935A (ja) 2021-04-23 2022-04-22 ＩｇＥ抗体を含む組成物

Country Status (10)

Country Link
US (1) US20240190955A1 (https=)
EP (1) EP4326770A1 (https=)
JP (1) JP2024514935A (https=)
KR (1) KR20240001136A (https=)
AU (1) AU2022263376A1 (https=)
BR (1) BR112023021873A2 (https=)
CA (1) CA3215850A1 (https=)
MX (1) MX2023012557A (https=)
WO (1) WO2022223784A1 (https=)
ZA (1) ZA202309456B (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
CN103037900B (zh) 2010-02-24 2016-04-06 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
CA2848842C (en) 2011-10-04 2020-09-29 King's College London Ige anti -hmw-maa antibody
RU2019141270A (ru) 2017-05-16 2021-06-16 Иммуноджен, Инк. Комбинации анти-folr1 иммуноконъюгатов и анти-pd-1 антител
GB202006093D0 (en) * 2020-04-24 2020-06-10 King S College London Composition

Also Published As

Publication number Publication date
EP4326770A1 (en) 2024-02-28
AU2022263376A9 (en) 2023-11-30
MX2023012557A (es) 2023-11-08
CA3215850A1 (en) 2022-10-27
WO2022223784A1 (en) 2022-10-27
AU2022263376A1 (en) 2023-11-23
ZA202309456B (en) 2025-03-26
BR112023021873A2 (pt) 2023-12-19
US20240190955A1 (en) 2024-06-13
KR20240001136A (ko) 2024-01-03

Similar Documents

Publication Publication Date Title
TWI726936B (zh) 對asct2具專一性之結合分子及其用途
US12441795B2 (en) Anti-ROR1 antibodies and preparation method and uses thereof
JP7383682B2 (ja) 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
CA2851762A1 (en) Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
AU2011378675A1 (en) IgE anti -HMW-MAA antibody
KR20230079409A (ko) 항-cd3 항체 및 이의 용도
CN112739716A (zh) 使用抗pd-1抗体与抗组织因子抗体-药物偶联物的组合治疗癌症的方法
TW202031686A (zh) 抗ｃｄ７９ｂ抗體、其抗原結合片段及其醫藥用途
JP2022513729A (ja) ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体
WO2021214329A1 (en) Composition comprising an ige antibody
US20250082771A1 (en) Dosage regimen of an anti-cdh6 antibody-drug conjugate
JP2020508636A (ja) ＩＦＮ−γ誘導性制御性Ｔ細胞転換性抗癌（ＩＲＴＣＡ）抗体およびその使用
KR20250122456A (ko) Fas 리간드에 특이적인 단일클론 항체 및 이의 용도
US20240190955A1 (en) Composition comprising an ige antibody
CN117203237A (zh) 包含IgE抗体的组合物
US12606617B2 (en) Composition comprising an IgE antibody
WO2026069561A1 (en) Anti-cd147 antibodies and methods of using the same
EP4653460A1 (en) Il18r agonist antibodies and uses thereof
WO2022255248A1 (ja) 抗ｃｄ２６抗体と免疫チェックポイント阻害剤との併用療法
WO2025003373A1 (en) Anti-her2 antibody for use in treating a low her2 expressing tumor in a subject
TW202400651A (zh) 抗cd200r1抗體
JP2025537099A (ja) 抗αＶβ６抗体および抗体－薬物コンジュゲートならびにがんの治療におけるそれらの使用
CN117715654A (zh) 包含抗-cd205抗体和免疫检查点抑制剂的药物组合
IL324392A (en) Antibodies targeting human leukocyte antigen cathepsin g peptide complex
EA052759B1 (ru) Антитела против pd-l1 и конъюгаты антитело-лекарственное средство

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250410